Selected research
Industry Research
Antihypertensive Drugs Industry Research Report 2026
Market perspective
The global Antihypertensive Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Antihypertensive Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Antihypertensive Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Antihypertensive Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Antihypertensive Drugs include Takeda, Sanofi, Johnson & Johnson, Novartis, Merck, Pfizer, United Therapeutics, Ranbaxy Laboratories and Lupin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Antihypertensive Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antihypertensive Drugs Market by Company
Takeda
Sanofi
Johnson & Johnson
Novartis
Merck
Pfizer
United Therapeutics
Ranbaxy Laboratories
Lupin
Daiichi Sankyo
Astra Zeneca
Actelion
Antihypertensive Drugs Segment by Type
Calcium Antagonist Medicine
Sympathetic Suppressant
Diuretic Antihypertensive
Renin-angiotensin System Inhibitor
vasodilator
Antihypertensive Drugs Segment by Application
Pregnant Woman
General Patient
The Old
Antihypertensive Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihypertensive Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antihypertensive Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihypertensive Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Antihypertensive Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Antihypertensive Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Antihypertensive Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Calcium Antagonist Medicine
- Sympathetic Suppressant
- Diuretic Antihypertensive
- Renin-angiotensin System Inhibitor
- vasodilator
Applications
- Pregnant Woman
- General Patient
- The Old
Companies covered
- Takeda
- Sanofi
- Johnson & Johnson
- Novartis
- Merck
- Pfizer
- United Therapeutics
- Ranbaxy Laboratories
- Lupin
- Daiichi Sankyo
- Astra Zeneca
- Actelion
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Antihypertensive Drugs Market Size (2021-2032)
- 2.2.2 Global Antihypertensive Drugs Sales (2021-2032)
- 2.2.3 Global Antihypertensive Drugs Market Average Price (2021-2032)
- 2.3 Antihypertensive Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Calcium Antagonist Medicine
- 2.3.3 Sympathetic Suppressant
- 2.3.4 Diuretic Antihypertensive
- 2.3.5 Renin-angiotensin System Inhibitor
- 2.3.6 vasodilator
- 2.4 Antihypertensive Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pregnant Woman
- 2.4.3 General Patient
- 2.4.4 The Old
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Antihypertensive Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Antihypertensive Drugs Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global Antihypertensive Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Antihypertensive Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Antihypertensive Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Antihypertensive Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Antihypertensive Drugs, Product Type & Application
- 3.8 Global Manufacturers of Antihypertensive Drugs, Established Date
- 3.9 Global Antihypertensive Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Antihypertensive Drugs Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Antihypertensive Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Johnson & Johnson
- 4.3.1 Johnson & Johnson Company Information
- 4.3.2 Johnson & Johnson Business Overview
- 4.3.3 Johnson & Johnson Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson & Johnson Antihypertensive Drugs Product Portfolio
- 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Antihypertensive Drugs Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Antihypertensive Drugs Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Antihypertensive Drugs Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 United Therapeutics
- 4.7.1 United Therapeutics Company Information
- 4.7.2 United Therapeutics Business Overview
- 4.7.3 United Therapeutics Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 United Therapeutics Antihypertensive Drugs Product Portfolio
- 4.7.5 United Therapeutics Recent Developments
- 4.8 Ranbaxy Laboratories
- 4.8.1 Ranbaxy Laboratories Company Information
- 4.8.2 Ranbaxy Laboratories Business Overview
- 4.8.3 Ranbaxy Laboratories Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Ranbaxy Laboratories Antihypertensive Drugs Product Portfolio
- 4.8.5 Ranbaxy Laboratories Recent Developments
- 4.9 Lupin
- 4.9.1 Lupin Company Information
- 4.9.2 Lupin Business Overview
- 4.9.3 Lupin Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lupin Antihypertensive Drugs Product Portfolio
- 4.9.5 Lupin Recent Developments
- 4.10 Daiichi Sankyo
- 4.10.1 Daiichi Sankyo Company Information
- 4.10.2 Daiichi Sankyo Business Overview
- 4.10.3 Daiichi Sankyo Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Daiichi Sankyo Antihypertensive Drugs Product Portfolio
- 4.10.5 Daiichi Sankyo Recent Developments
- 4.11 Astra Zeneca
- 4.11.1 Astra Zeneca Company Information
- 4.11.2 Astra Zeneca Business Overview
- 4.11.3 Astra Zeneca Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Astra Zeneca Antihypertensive Drugs Product Portfolio
- 4.11.5 Astra Zeneca Recent Developments
- 4.12 Actelion
- 4.12.1 Actelion Company Information
- 4.12.2 Actelion Business Overview
- 4.12.3 Actelion Antihypertensive Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Actelion Antihypertensive Drugs Product Portfolio
- 4.12.5 Actelion Recent Developments
5 Global Antihypertensive Drugs Market Scenario by Region
- 5.1 Global Antihypertensive Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Antihypertensive Drugs Sales by Region: 2021-2032
- 5.2.1 Global Antihypertensive Drugs Sales by Region: 2021-2026
- 5.2.2 Global Antihypertensive Drugs Sales by Region: 2027-2032
- 5.3 Global Antihypertensive Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Antihypertensive Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Antihypertensive Drugs Revenue by Region: 2027-2032
- 5.4 North America Antihypertensive Drugs Market Facts & Figures by Country
- 5.4.1 North America Antihypertensive Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Antihypertensive Drugs Sales by Country (2021-2032)
- 5.4.3 North America Antihypertensive Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Antihypertensive Drugs Market Facts & Figures by Country
- 5.5.1 Europe Antihypertensive Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Antihypertensive Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Antihypertensive Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Antihypertensive Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Antihypertensive Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Antihypertensive Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Antihypertensive Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Antihypertensive Drugs Market Facts & Figures by Country
- 5.7.1 South America Antihypertensive Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Antihypertensive Drugs Sales by Country (2021-2032)
- 5.7.3 South America Antihypertensive Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Antihypertensive Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Antihypertensive Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Antihypertensive Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Antihypertensive Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Antihypertensive Drugs Sales by Type (2021-2032)
- 6.1.1 Global Antihypertensive Drugs Sales by Type (2021-2032) & (M Pcs)
- 6.1.2 Global Antihypertensive Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Antihypertensive Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Antihypertensive Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Antihypertensive Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Antihypertensive Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Antihypertensive Drugs Sales by Application (2021-2032)
- 7.1.1 Global Antihypertensive Drugs Sales by Application (2021-2032) & (M Pcs)
- 7.1.2 Global Antihypertensive Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Antihypertensive Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Antihypertensive Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Antihypertensive Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Antihypertensive Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Antihypertensive Drugs Value Chain Analysis
- 8.1.1 Antihypertensive Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Antihypertensive Drugs Production Mode & Process
- 8.2 Antihypertensive Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Antihypertensive Drugs Distributors
- 8.2.3 Antihypertensive Drugs Customers
9 Global Antihypertensive Drugs Analyzing Market Dynamics
- 9.1 Antihypertensive Drugs Industry Trends
- 9.2 Antihypertensive Drugs Industry Drivers
- 9.3 Antihypertensive Drugs Industry Opportunities and Challenges
- 9.4 Antihypertensive Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst